Novavax Stock News

Novavax, Inc. (NASDAQ:NVAX) shares traded down 3.7% on Wednesday after an insider sold shares in the company. The company traded as low as $195.00 and last traded at $201.00. 22,483 shares were traded during mid-day trading, a decline of 100% from the average session volume of 4,637,793 shares. The stock had previously closed at $208.63. []

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nio, Ford, Novavax and CrowdStrike were our top stock trades for Friday. With that in mind, let''s look at how the charts are shaping up now. The post 4 Top Stock Trades for Friday: NIO, F, NVAX, CRWD appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First

The Omicron coronavirus variant has shaken up markets and caused global alarm over concerns about whether it could evade protection provided by widely used vaccines and prolong the public health crisis. Other vaccine makers including Moderna and Pfizer have also begun working on Omicron-tailored COVID-19 shots. Novavax''s COVID-19 vaccine received its first emergency use approval in Indonesia in early November followed by the Philippines.

Novavax Inc. unveiled on Thursday that it has started on the initial steps required to manufacture an Omicron-specific coronavirus vaccine, with the manufacturing of the vaccine in a commercial facili

(PR-inside.com) SAN FRANCISCO, CA / ACCESSWIRE / December 2, 2021 / Hagens Berman urges Novavax, Inc. (NASDAQ:NVAX) investors with significant losses to submit your losses now. Class Period: Mar. 2, 2021 - Oct. 19, 2021 Lead Plaintiff Deadline: Jan. 11, 2022 Visit: www.hbsslaw.com/investor-fraud/NVAX Contact An Attorney Now: [email protected] 844-916-0895 Novavax, Inc. (NVAX) Securities Fraud Class Action: The lawsuit alleges that Defendants misrepresented Novavax''s progress toward successfully developing its COVID-19 vaccine (NVX-CoV2373), including: (1) overstating Novavax''s manufacturing capabilities and downplaying manufacturing issues that would impact the approval timeline for NVX-CoV2373; (2) concealing that Novavax was unlikely to meet its anticipated EUA regulatory timelines; (3) exaggerating the regulatory and commercial ..

In short: Not really.

NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn''t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor''s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

SAN DIEGO--(BUSINESS WIRE)---- $NVAX #COVID19--Novavax, Inc. (NVAX) Misled Shareholders Regarding Approval of its COVID Vaccine

The world''s biggest vaccine maker exported 137,500 doses of Covovax, as it calls the shot, to the Southeast Asian country last week

Serum Institute of India (SII) has exported its first Novavax doses to Indonesia by the COVAX network, the Indian government declared. The worlds biggest vaccine maker exported 1,37,500 doses of Covovax to Indonesia last week. Indonesia has already approved the Novavax dose, but India and the World Health Organization (WHO) The post SII Exports 1st Novavax Dose Through COVAX appeared first on Equitypandit .

Exported 137,500 doses of Covovax to Indonesia

CEDARHURST, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Höegh LNG Partners LP (HMLP) Class Period: August 22, 2019 and July 27, 2021 Lead Plaintiff Motion Deadline: December 27, 2021 SECURITIES FRAUD To learn more, visit https://kclasslaw.com/cases/securities/nyse-hmlp/ ON24, Inc. (ONTF) Class Period: purchase of shares issued either in or after the February 2021 Initial Public Offering Lead Plaintiff Motion Deadline: January 3, 2022 MISLEADING PROSPECTUS To learn more, visit https://kclasslaw.com/cases/securities/nyse-ontf/ Novavax, Inc. (NVAX) Class Period: March Full story available on Benzinga.com

Read more about India''s Serum Institute delivers first Novavax shot through COVAX on Devdiscourse

The Novavax two-dose shot is made with lab-grown copies of the spike protein that coats the coronavirus.